CORONAVIRUS DRUG: GILEAD TO END REMDESIVIR TRIALS
Sat 16 May 2020: According to the US National Institutes of Health, studies showed remdesivir cut hospital stays by 31 percent. Gilead Sciences Inc’s two clinical studies of its potential coronavirus treatment remdesivir will wind down by the end of May. The end of these trials effectively closes off a path of patient access to […]
Continue Reading
